IAM
CTKB icon

Innovis Asset Management’s Cytek Biosciences CTKB Stock Holding History

Innovis Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,565
Closed -$149K – 164
2022
Q4 		$149K Buy
+14,565
New +$196K 0.07% 145

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Innovis Asset Management's CTKB Position: Q1 2023 in Review

Innovis Asset Management sold out of Cytek Biosciences (CTKB) in Q1 2023, closing a stake of 14,565 shares — an estimated $149K sold.

Innovis Asset Management first reported a position in CTKB in Q4 2022 and held it in 1 quarter. The position peaked at $149K in Q4 2022. 102 funds tracked by Wall St. Rank hold CTKB as of Q1 2023.

  • Innovis Asset Management reported no remaining Cytek Biosciences position as of Q1 2023 after selling out during the quarter.
  • Innovis Asset Management sold 14,565 Cytek Biosciences shares in Q1 2023, an estimated $149K.
  • Innovis Asset Management first reported a position in Cytek Biosciences in Q4 2022 and held it in 1 quarter.
  • Innovis Asset Management's Cytek Biosciences position peaked at $149K in Q4 2022.
  • 102 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2023.

Based on Innovis Asset Management's 13F filing for Q1 2023, filed 10 May 2023.